Bristol Myers Squibb Growth Portfolio Revenue Reaches $7.7 Billion
BMY Bristol-Myers Squibb Co
$58.80 +0.79%
View chart & analysis → - 1Bristol Myers Squibb recorded $7.7 billion in growth portfolio revenue for a single quarter.
- 2As of the third quarter, the growth portfolio accounts for approximately 60% of Bristol Myers Squibb's total drug sales.
- 3Eliquis is expected to face generic competition starting around 2028.
So what's the key point?
Bristol Myers Squibb's growing drug revenue reached $7.7 billion. It is important to note that Eliquis will face competition from generic drugs starting around 2028.
Source The Motley Fool +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.